MEBEA AKLILU MD
Prescription History 1376527739
Internal Medicine - Medical Oncology in Chicago, IL

NPI Status: Active since November 30, 2005

Contact Information

901 W WELLINGTON AVE
CHICAGO, IL
ZIP 60657
Phone: (773) 296-7248

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MEBEA AKLILU MD, an active Medical Oncology specialist practicing in Chicago, IL. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 363 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisone, which accounts for 93 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 88
30-Day Fills 88.0
Days Supply 2,640
IL State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills41.9
Peer Average Days Supply1,248
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 120.0% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $379,325.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,310.52

State Avg Cost Per Claim

$2,441.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.6
Days Supply 357
IL State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply453
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.3% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $702.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.58

State Avg Cost Per Claim

$16.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
IL State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.2
Peer Average Days Supply625
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,635.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$125.79

State Avg Cost Per Claim

$1,812.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 26.3
Days Supply 262
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply409
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $160.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.43

State Avg Cost Per Claim

$6.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 85
IL State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply214
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $122.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.78

State Avg Cost Per Claim

$19.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 93
30-Day Fills 111.0
Days Supply 3,162
IL State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills55.3
Peer Average Days Supply1,013
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 106.7% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $551.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.93

State Avg Cost Per Claim

$6.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 333
IL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.3
Peer Average Days Supply350
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 31.3% more claims than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $549.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.09

State Avg Cost Per Claim

$16.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 76
30-Day Fills 76.0
Days Supply 2,280
IL State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills33.1
Peer Average Days Supply986
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 137.5% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,112,586.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,639.30

State Avg Cost Per Claim

$13,416.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MEBEA AKLILU MD provides transparency into local medical care patterns within Chicago, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.